The company behind an imaging agent meant to identify prostate cancer said it received FDA approval on Thursday for use in patients with suspected metastasis or recurrence. Lantheus Holdings, Inc.

Prostate cancer is the second most common cancer in men, with over 288,000 new cases diagnosed each year. It is also one of the most curable cancers if detected early. A new imaging tool is helping ...

The NHS is embarking on a trial that could cut prostate cancer diagnosis times from weeks to a single day. The initiative ...

A new study is set to investigate how AI could significantly improve doctors’ decisions regarding prostate cancer treatment. While diagnostic methods for the disease have become safer and more precise ...

Don't miss out on the headlines from QLD News. Followed categories will be added to My News. The prostate specific antigen test, or PSA test, screens for elevated levels of a protein in a man’s blood ...

Each year, more than one million men in the United States have a prostate biopsy due to an elevated PSA. The majority of these biopsies show either no prostate cancer or low-risk cancer, meaning the ...

Researchers at the Center for Computational Imaging and Personalized Diagnostics (CCIPD) at Case Western Reserve University have preliminarily validated an artificial intelligence (AI) tool to predict ...

Innovative technology performs automatic segmentation and lesion detection in prostate MRI scans to assist in PI-RADS scoring for prostate cancer management TEL AVIV, Israel & SAN JOSE, ...

A Singapore-based startup has launched a new Artificial Intelligence module, QAi Prostate that analyses whole slide images for accurate prostate cancer diagnosis. An advanced ...